Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions | PAYS Stock News

Dynamic Business Rules Demonstrates the Company’s Advanced Capabilities in Mitigating Copay Maximizers, Exiting 2025 With 131 Active Programs HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions and integrated payment processing for the life sciences industries, today announced its annual performance analysis of pharmaceutical copay programs. The company added 55 programs during 2025, exiting the year with 131 programs – many incorporating Paysign’s Dynamic Business Rules feature, which saved pharmaceutical clients more than $325 million by mitigating the harmful financial impact of copay maximizers on patients and program sponsors.Dynamic Business Rules identifies impacted claims on the first prescription fill with 97 percent accuracy – an industry first and unique capability that has established the technology as a cornerstone of Paysign’s patient affordability business.Paysign’s innovative patient affordability solutions achieved these results in 2025:Saved more than $325 million for pharmaceutical program sponsors by preventing funds diversion, an increase of more than 200% from 2024Supported 131 retail and specialty pharmaceutical programs across diverse therapeutic classes, greater than 70% increase from 2024Assisted more than 840,000 unique patientsAssisted pharmaceutical clients in delivering more than $950 million toward prescription fulfillment expenses“2025 was an outstanding year for this business,” said Matt Turner, President of Patient Affordability at Paysign. “New financial threats emerge annually for our clients and their patients. Our continued focus on these challenges delivers lasting value for our clients and ensures patients maintain access to critical therapies. As we enter 2026, we are more driven than ever to identify and mitigate program risks that increase costs for pharmaceutical manufacturers by providing lifesaving patient affordability solutions designed to reduce the cost of healthcare in America.”The 2025 results demonstrate Paysign’s expanding presence across the healthcare ecosystem. Substantial growth in patient and client savings highlights the advanced efficacy of the company’s solutions and underscores its ability to deliver greater value to patients and pharmaceutical program sponsors.“Reaching these significant milestones reflects the innovative drive at the heart of our patient affordability solutions,” said Mark Newcomer, Chief Executive Officer of Paysign. “Paysign continues to grow within healthcare and life sciences, and we remain committed to advancing our solutions to better serve our partners and patients.”Paysign’s innovative patient affordability platform offers tools that can be configured to the specific needs of each copay assistance program and pharmaceutical manufacturers’ brand strategies. Paysign’s proprietary Dynamic Business Rules enables real-time modifications to program criteria to reduce the impact of copay maximizers, ensuring seamless benefit experiences for patients and providers. Visit paysign.com/rx to learn more about Paysign’s patient affordability offerings.About PaysignPaysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.Forward-Looking StatementsCertain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.View source version on businesswire.com: https://www.businesswire.com/news/home/20260107031834/en/Investor Relationsir@paysign.com888.522.4853paysign.com/investorsMedia RelationsAlicia Ches888.522.4850pr@paysign.comSource: Paysign, Inc.